Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Duchenne Muscular Dystrophy (Exon 51 Skipping)
2019-000337-39Phase 2
- Sponsor
- Sarepta Therapeutics
- Start
- Apr 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoint: Incidence of AEs, SAEs, and discontinuation from treatment due to AEs.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-000337-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000337-39.